Table 1.
Patient Characteristics at Baseline, Including Tocilizumab Recipients, All Controls, and Matched Controls
| Tocilizumab (n = 90) | Control Group (n = 1669) | Matched Group (n = 90) | |
|---|---|---|---|
| Demographics | |||
| Median age (IQR), y | 63 (9) | 61 (14) | 63.5 (10) |
| Male | 71 (78.9) | 864 (51.8) | 70 (77.8) |
| Race Black | 28 (31.1) | 585 (35.1) | 31 (34.4) |
| Race Hispanic | 30 (33.3) | 473 (28.3) | 31 (34.4) |
| Race White | 15 (16.7) | 448 (26.8) | 15 (16.7) |
| Race other | 17 (18.9) | 163 (9.8) | 13 (14.4) |
| Median BMI (IQR), kg/m2 | 28.4 (3.4) | 28.6 (4.7) | 27.7 (4.4) |
| Ever DNR/DNI | 38 (42.2) | 388 (23.2) | 41 (45.6) |
| Comorbidities | |||
| Hypertension | 44 (48.9) | 793 (47.5) | 36 (40) |
| Coronary artery disease | 29 (32.2) | 517 (31) | 33 (36.7) |
| Congestive heart failure | 18 (20) | 250 (15) | 20 (22.2) |
| Chronic kidney disease | 14 (15.6) | 199 (11.9) | 13 (14.4) |
| Diabetes | 35 (38.9) | 476 (28.5) | 34 (37.8) |
| Asthma | 4 (4.4) | 138 (8.3) | 3 (3.3) |
| COPD/chronic lung disease | 10 (11.1) | 260 (15.6) | 17 (18.9) |
| Cancer | 6 (6.7) | 169 (10.1) | 9 (10) |
| Liver disease | 4 (4.4) | 86 (5.2) | 4 (4.4) |
| HIV | 1 (1.1) | 21 (1.3) | 1 (1.1) |
| Transplant | 5 (5.6) | 23 (1.4) | 0 (0) |
| CCI 0 | 34 (37.8) | 660 (39.5) | 31 (34.4) |
| CCI 1–4 | 53 (58.9) | 944 (56.6) | 54 (60) |
| CCI ≥5 | 3 (3.3) | 65 (3.9) | 5 (5.6) |
| Concomitant medications | |||
| Hydroxychloroquine | 25 (27.8) | 381 (22.8) | 24 (26.7) |
| Azithromycin | 56 (62.2) | 670 (40.1) | 50 (55.6) |
| Dexamethasone | 6 (6.7) | 75 (4.5) | 13 (14.4) |
| Prednisone | 10 (11.1) | 87 (5.2) | 2 (2.2) |
| Heparin (prophylaxis or treatment dose) | 69 (76.7) | 1217 (72.9) | 71 (78.9) |
| Remdesivir | 17 (18.9) | 157 (9.4) | 17 (18.9) |
| Trial participation | 1 (1.1) | 54 (3.2) | 10 (11.1) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; DNR/DNI, do-not-resuscitate, do-not-intubate; IQR, interquartile range.